Sage Therapeutics (SAGE) PT Raised to $30 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $30.00 (from $26.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Nextpower (NXT) PT Raised to $158 at GLJ Research
- Hapvida Participacoes e Investimentos SA (HAPV3:BZ) PT Lowered to R$5.60 at UBS
- FMC Corp. (FMC) PT Lowered to $6.50 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
